Axsome Therapeutics Acquires AZD7325, a Novel GABA-A Receptor Positive Allosteric Modulator for Epilepsy Treatment
ByAinvest
Thursday, Nov 6, 2025 7:03 am ET1min read
AXSM--
AZN--
Axsome Therapeutics has acquired AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator licensed from AstraZeneca, to treat epilepsy. AZD7325 has completed Phase 1 trials and demonstrated anti-convulsant effects in preclinical seizure models. Axsome plans to begin Phase 2 trial-enabling activities in 2026 and has acquired Baergic Bio, Inc. to receive worldwide commercial, development, and manufacturing rights to AZD7325.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet